These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978 [Abstract] [Full Text] [Related]
5. In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography? Kulkarni SC, Sundaram PS, Padma S. Nucl Med Commun; 2020 Feb; 41(2):139-146. PubMed ID: 31714366 [Abstract] [Full Text] [Related]
8. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C. Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842 [Abstract] [Full Text] [Related]
9. Correlations of the 68Ga-PSMA PET/CT derived primary prostate tumor PSMA expression parameters and metastatic patterns in patients with Gleason Score >7 prostate cancer. Karyagar SS, Karyagar S, Guven O. Hell J Nucl Med; 2020 Dec; 23(2):120-124. PubMed ID: 32716402 [Abstract] [Full Text] [Related]
10. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H. J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970 [Abstract] [Full Text] [Related]
11. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C. Eur J Nucl Med Mol Imaging; 2017 Jan 07; 44(1):92-101. PubMed ID: 27557844 [Abstract] [Full Text] [Related]
12. Clinical impact of PSMA PET/CT in primary prostate cancer compared to conventional nodal and distant staging: a retrospective single center study. Donswijk ML, van Leeuwen PJ, Vegt E, Cheung Z, Heijmink SWTPJ, van der Poel HG, Stokkel MPM. BMC Cancer; 2020 Aug 05; 20(1):723. PubMed ID: 32758168 [Abstract] [Full Text] [Related]
13. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer? Raju S, Sharma A, Patel C, Sahoo R, Das CJ, Kumar S, Sharma A, Kumar R. Nucl Med Commun; 2020 Nov 05; 41(11):1183-1188. PubMed ID: 32796451 [Abstract] [Full Text] [Related]
14. Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference. Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A. Mol Imaging Biol; 2020 Jun 05; 22(3):788-796. PubMed ID: 31482413 [Abstract] [Full Text] [Related]
15. Frusemide aids diagnostic interpretation of 68 Ga-PSMA positron emission tomography/CT in men with prostate cancer. Fennessy N, Lee J, Shin J, Ho B, Ali SA, Paschkewitz R, Emmett L. J Med Imaging Radiat Oncol; 2017 Dec 05; 61(6):739-744. PubMed ID: 28623852 [Abstract] [Full Text] [Related]
16. Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse. Regula N, Kostaras V, Johansson S, Trampal C, Lindström E, Lubberink M, Velikyan I, Sörensen J. Sci Rep; 2020 Mar 19; 10(1):4993. PubMed ID: 32193430 [Abstract] [Full Text] [Related]